Findings from Paratek Pharmaceuticals Inc. Provides New Data about Bacillus anthracis (Omadacycline Is Active in Vitro and in Vivo Against Ciprofloxacin-resistant bacillus Anthracis).

A recent study conducted by Paratek Pharmaceuticals Inc. has found that omadacycline, an antibiotic, is effective against ciprofloxacin-resistant Bacillus anthracis, the bacteria that causes anthrax. The study assessed the in vitro activity and in vivo efficacy of omadacycline against clinical isolates of B. anthracis, including a ciprofloxacin-resistant strain. The results showed that omadacycline demonstrated both in vitro activity and in vivo efficacy against B. anthracis, suggesting that it may be a potential treatment option for inhalation anthrax caused by antibiotic-resistant strains. As antibiotic resistance rates continue to rise, omadacycline could provide an alternative treatment option for anthrax. [Extracted from the article]